Glycosylation is one of the most common and complex post-translational modifications, playing crucial roles in protein folding, stability, cell-cell recognition, and signaling. This page explores how glycosylation abnormalities contribute to neurodegenerative diseases.
Glycosylation involves the enzymatic attachment of carbohydrate moieties (glycans) to proteins or lipids. Approximately 50-70% of human proteins are glycosylated, making it one of the most prevalent post-translational modifications. In the nervous system, glycosylation is essential for synaptic function, neural development, and protein quality control. [1]
N-linked glycosylation occurs on asparagine residues within the consensus sequence Asn-X-Ser/Thr. This process begins in the endoplasmic reticulum (ER) and continues in the Golgi apparatus.
High-mannose type: Contains only mannose residues on the core chitobiose unit. This form is typically found on ER-resident proteins and serves as a quality control checkpoint.
Complex type: Contains additional sugars including N-acetylglucosamine (GlcNAc), galactose, fucose, and sialic acid. These are the most diverse N-glycans and are predominant on cell surface proteins.
Hybrid type: Combines features of high-mannose and complex types, with mannose residues on one branch and complex sugars on others.
The N-glycan processing pathway begins in the ER with the removal of glucose residues from the initial Glc3Man9Glc2 structure, followed by trimming in the Golgi to generate the various glycoforms. [2]
O-linked glycosylation occurs on serine or threonine residues, typically in the Golgi apparatus. Unlike N-glycosylation, there is no strict consensus sequence, making prediction more challenging.
Mucin-type O-glycans: Core 1 (Galβ1-3GalNAcα1-Ser/Thr) and core 2 (Galβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr) are the most common. Extended mucin-type glycans can become very large and heavily sialylated.
O-GlcNAc: A single N-acetylglucosamine attached to serine or threonine residues on nuclear and cytoplasmic proteins. Unlike other O-glycans, O-GlcNAc is reversible and dynamic, serving as a nutrient and stress sensor. The enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) regulate this modification. [3]
Fucose and xylose linkages: Found on extracellular matrix proteins and growth factor receptors. These modifications are crucial for ligand binding and receptor activation.
C-mannosylation: Rare modification on tryptophan residues within the consensus sequence Trp-X-X-Trp. Found in proteins with thrombospondin-type repeats.
Glypiation: GPI anchor attachment for membrane proteins. The GPI anchor is synthesized in the ER and added to the C-terminus of proteins, anchoring them to the plasma membrane.
Glycosaminoglycans: Long, unbranched polysaccharides including heparan sulfate, chondroitin sulfate, and keratan sulfate, attached to core proteins to form proteoglycans.
Numerous synaptic proteins are heavily glycosylated, and proper glycosylation is essential for their function:
Synaptic cell adhesion molecules (SynCAM): Require proper glycosylation for homophilic interactions across the synaptic cleft. The glycan modifications on SynCAM affect its ability to induce synapse formation.
Neuroligins and neurexins: Glycosylation affects synaptic adhesion strength and specificity. Alternative splicing creates isoforms with different glycan profiles.
AMPA and NMDA receptor subunits: Glycosylation influences trafficking, localization, and function. NMDA receptor glycosylation affects channel properties and synaptic plasticity. [4]
GluA1-4 (AMPA receptors): Differ in their glycan composition, affecting their trafficking and synaptic retention.
Myelin proteins contain unique glycosylation patterns essential for white matter integrity:
Myelin oligodendrocyte glycoprotein (MOG): Heavily glycosylated on its extracellular domain. MOG is a major autoantigen in multiple sclerosis and its glycosylation status affects antibody recognition.
Myelin basic protein (MBP): Contains unique glycosylation that affects its membrane association and compaction properties.
Proteolipid protein (PLP): Modified with glycans that affect its trafficking to myelin sheaths. [5]
Brain-expressed glycosyltransferases are essential for neural development and function:
ST8Sia2 (STX): Alpha-2,8-sialyltransferase involved in polysialic acid (PSA) synthesis on neural cell adhesion molecule (NCAM). PSA-NCAM is crucial for synaptic plasticity and neural migration.
B3GAT3: Beta-1,3-glucuronyltransferase involved in glycosaminoglycan synthesis.
MGAT5: N-acetylglucosaminyltransferase V, responsible for creating beta-1,6-GlcNAc branches on N-glycans. This enzyme is involved in tumor metastasis and immune cell function.
POMGNT1 and POMT1: Protein O-mannosyltransferases required for the glycosylation of alpha-dystroglycan, essential for muscle and brain development.
Multiple glycosylation abnormalities have been documented in Alzheimer's disease:
APP Glycosylation
Proper glycosylation affects amyloid precursor protein (APP) processing and amyloid-beta (Aβ) generation. The glycosylation status of APP influences its trafficking through the secretory pathway and its susceptibility to proteolytic cleavage by β- and γ-secretases. [6]
Tau Glycosylation
Tau protein undergoes extensive glycosylation in the brain. In AD:
BACE1 Glycosylation
β-secretase (BACE1) requires proper glycosylation for its catalytic activity. Changes in BACE1 glycosylation in AD may affect amyloid production.
Synaptic Glycoprotein Changes
Alpha-Synuclein Glycosylation
Alpha-synuclein (α-syn) is modified by O-GlcNAc, which may regulate its aggregation:
Lysosomal Enzyme Glycosylation
Proper glycosylation of lysosomal enzymes is essential for their trafficking and function. In PD:
TDP-43 Glycosylation
TDP-43 is the major component of inclusions in ALS. Glycosylation of TDP-43:
Neuronal Glycosylation Changes
Huntingtin Glycosylation
The huntingtin protein contains multiple glycosylation sites:
Glycosylation plays a crucial role in protein quality control:
N-glycan-based quality control
Lectin-based ERAD
Glycan involvement in autophagy
Enzyme inhibitors
Glycan-based therapies
Dietary influences on glycosylation
Supplementation strategies
Glycosyltransferase modulation
Glycan biomarkers
Glyco-proteomics
Glycosyltransferase knockouts
Glycosylation diseases
Analysis methods
Single-cell glycomics
Personalized glycomedicine
Glycosylation in the central nervous system (Glycobiology, 2018). 2018. ↩︎
N-linked glycosylation in Alzheimer's disease (J Neurochem, 2020). 2020. ↩︎
O-GlcNAc in neurodegeneration (Nat Rev Neurosci, 2021). 2021. ↩︎
NMDA receptor glycosylation in synaptic plasticity (Neuron, 2019). 2019. ↩︎
Myelin glycoprotein changes in disease (Glia, 2022). 2022. ↩︎
APP glycosylation and amyloidogenesis (J Biol Chem, 2017). 2017. ↩︎
Tau glycosylation in Alzheimer's disease (Acta Neuropathol, 2020). 2020. ↩︎
Alpha-synuclein O-GlcNAcylation (Nat Commun, 2019). 2019. ↩︎
Glycosylation in autophagy regulation (Autophagy, 2023). 2023. ↩︎
Dietary modulation of glycosylation (Nutrients, 2024). 2024. ↩︎
Glycan biomarkers for neurodegeneration (Alzheimer's Dement, 2024). 2024. ↩︎